| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Multiple targets: androgen receptor (AR), pyruvate dehydrogenase kinase (PDK), and mitochondrial function pathways.
|
|---|---|
| ln Vitro |
The viability of LNCaP and C4-2 cells is inhibited by honokiol DCA (20–40 μM; 24-48 hours) in a dose- and time-dependent manner [1]. The clonogenesis of prostate cancer cells is inhibited by honokiol DCA (5–20 μM; 10 days) [1]. In LNCaP cells, honokiol DCA (20–40 μM; 24-48 hours) dramatically lowers the levels of the proteins androgen receptor (AR) and prostate-specific antigen (PSA) [1]. In LNCaP and C4-2 cells, honokiol DCA (40 μM; 24 hours) dramatically lowers AR promoter activity [1].
Honokiol DCA inhibits the growth of human prostate cancer cells in vitro and suppresses androgen receptor (AR) protein levels. It synergistically induces apoptosis, reduces tumor growth, and disrupts mitochondrial function more effectively than either honokiol or DCA alone. The compound shows anticancer activity through combined effects on AR signaling and mitochondrial metabolism. |
| ln Vivo |
Analogs of Magnolia officinalis
In vivo, Honokiol DCA demonstrates activity against vemurafenib-resistant melanoma (LM36R). The compound has antitumor activity in preclinical models, showing reduced tumor growth and enhanced apoptosis. Specific dosing regimens and detailed efficacy data are available in the literature but not detailed in public search results. |
| Enzyme Assay |
Androgen receptor protein level is assessed by Western blot in prostate cancer cells treated with Honokiol DCA. PDK inhibition is measured by assessing pyruvate dehydrogenase activity. Mitochondrial function is evaluated by measuring oxygen consumption rate and ATP production. Cell proliferation is assessed by MTT or colony formation assays.
|
| Cell Assay |
Cellular activity is evaluated in human prostate cancer cell lines and melanoma cells. Cells are treated with Honokiol DCA at various concentrations and cell viability is measured. AR protein levels are assessed by Western blot. Apoptosis is measured by caspase activation or Annexin V staining. Mitochondrial function is assessed using Seahorse metabolic assays.
|
| Animal Protocol |
In vivo efficacy is studied in mouse xenograft models of cancer, including vemurafenib-resistant melanoma. Honokiol DCA is administered orally or via intraperitoneal injection. Tumor growth is measured over time. Apoptosis and mitochondrial function are assessed in tumor tissue. Pharmacodynamic markers including AR levels and PDK activity are evaluated.
|
| ADME/Pharmacokinetics |
Honokiol DCA has a molecular formula of C22H18Cl4O4 and molecular weight of 488.19. It is soluble in DMSO (up to 50 mg/mL). The compound is typically provided as a viscous oil. Purity is typically ≥95%. The compound is a dichloroacetate ester of honokiol.
|
| Toxicity/Toxicokinetics |
Safety data for Honokiol DCA indicate it is a research compound for laboratory use only. Specific toxicological profiles including acute toxicity, organ toxicity, and genotoxicity are not extensively published. As a PDK inhibitor and mitochondrial modulator, it may affect cellular metabolism. Standard laboratory safety practices should be followed during handling.
|
| References | |
| Additional Infomation |
Honokiol DCA is a research compound combining the natural product honokiol with dichloroacetate. It is not approved for clinical use. The compound has been investigated for cancer research due to its dual mechanism targeting androgen receptor signaling and mitochondrial metabolism. It shows potential for overcoming resistance to targeted therapies such as vemurafenib.
|
| Molecular Formula |
C22H18CL4O4
|
|---|---|
| Molecular Weight |
488.19
|
| Exact Mass |
485.995
|
| CAS # |
1620160-42-0
|
| PubChem CID |
86287577
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
7.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
30
|
| Complexity |
610
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=CCC1=CC(=C(C=C1)OC(=O)C(Cl)Cl)C2=CC(=C(C=C2)OC(=O)C(Cl)Cl)CC=C
|
| InChi Key |
KSJLHVAHFGNFFU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H18Cl4O4/c1-3-5-13-7-9-18(30-22(28)20(25)26)16(11-13)14-8-10-17(15(12-14)6-4-2)29-21(27)19(23)24/h3-4,7-12,19-20H,1-2,5-6H2
|
| Chemical Name |
[4-[2-(2,2-dichloroacetyl)oxy-5-prop-2-enylphenyl]-2-prop-2-enylphenyl] 2,2-dichloroacetate
|
| Synonyms |
Honokiol Bis-Dichloroacetate; Honokiol DCA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~204.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.12 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0484 mL | 10.2419 mL | 20.4838 mL | |
| 5 mM | 0.4097 mL | 2.0484 mL | 4.0968 mL | |
| 10 mM | 0.2048 mL | 1.0242 mL | 2.0484 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
